Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study finds different types of crystalloid fluids are equally effective for pediatric sepsis

25

Apr 2026

Study finds different types of crystalloid fluids are equally effective for pediatric sepsis

A major study, led by researchers at Children's Hospital of Philadelphia, Nemours Children's Health, and Children's National Hospital and involving an extensive network of medical centers across the United States and abroad, found that different types of crystalloid fluid resuscitation were equally effective for staving off the most serious adverse kidney events after the treatment of pediatric patients with suspected septic shock.

Molecular map reveals how Down syndrome alters brain development

25

Apr 2026

Molecular map reveals how Down syndrome alters brain development

Scientists at UCLA have created one of the first cellular-resolution molecular maps detailing how Down syndrome alters human brain development before birth - a resource that resolves longstanding contradictions in the field and could lay the groundwork for future therapeutic strategies.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.